Latest in Lilly’s Weekly
Sort by
9 items
-
Eli Lilly CEO expects new weight loss pill to be approved next year
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.CNBC - 1d -
Eli Lilly strikes deal for cancer treatment, gives timeline for weight loss pill
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.CNBC - 1d -
Weekly quiz: Zendaya looked happy but who else sparkled at the Golden Globes?
How much attention did you pay to what has been going on in the world over the past seven days?BBC News - 5d -
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.CNBC - 5d -
Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment costs about $1,000 a month without insurance.MarketWatch - 6d -
Eli Lilly's lead in the obesity race has grown. Its recent stock performance says otherwise
Eli Lilly has been one of the worst-performing Club stocks over the past six months.CNBC - 6d -
Oil prices score weekly gains, buoyed by China policy support
Oil futures posted solid gains in a holiday-shortened week, buoyed by expectations of further stimulus in China, the world’s largest crude importer, to boost its sputtering economy.MarketWatch - Jan. 3 -
Weekly quiz: Who beat Sabrina Carpenter to the best-selling song of 2024?
How closely have you been paying attention to what's been going on in the world over the past seven days?BBC News - Jan. 2